Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?

References

• Tastsch MF, Nitrini R, Neto MRL. Dementia with Lewy bodies: a distinct entity with specific treatment? Rev Bras Psiquiatr 2002;24:152–6.
   Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6.
   PubMed Web of Science ®Google Scholar
• Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord 2011;13(5):1–27.
   Google Scholar
• Aarsland D, Rongve A, Nore SP, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008;26(5):445–52.
   PubMed Web of Science ®Google Scholar
• Rahkonen T, Eloniemi-Sulkava U, Rissanen S, et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74(6):720–24.
   PubMed Web of Science ®Google Scholar
• Walker Z, McKeith I, Rodda J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open 2012;2:380.
   Web of Science ®Google Scholar
• Caramelli P, Barbosa MT. How to diagnose the four most frequent causes of dementia. Rev Bras Psiquiatr 2002;24:7–10.
   Google Scholar
• Bono GF, Simão-Silva DP, Batistela MS, et al. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer´s disease in a Southern Brazilian population. Neurochem Int 2014;81:57–62.
   Web of Science ®Google Scholar
• Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273–8.
   PubMed Web of Science ®Google Scholar
• Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:18521–3.
   Web of Science ®Google Scholar
• Wadih TJ, Navarro A, Peralta LA, et al. The neurochemistry and neuropharmacology of diffuse Lewy body disease. Rev Neurol 2006;42:549–55.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Davies P, Mayeux R, et al. Diffuse Lewy body disease. Neurophatological and biochemical studies of six patients. Acta Neurophatol 1987;75:8–15.
   PubMed Web of Science ®Google Scholar
• Tiraboshi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in disease whit Lewy bodies. Neurology 2000;54:407–11.
   PubMed Web of Science ®Google Scholar
• Maetzler W, Keller S, Michelis J, et al. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 2009;35:296–301.
   PubMed Web of Science ®Google Scholar
• Savica R, Murray ME, Persson XM, et al. Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. Alzheimer's Dement (Amst) 2016;3:43–50.
   PubMedGoogle Scholar
• Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouk Czech Repub 2011;155:219–30.
   PubMed Web of Science ®Google Scholar
• Arpagaus M, Kott M, Vatsis KP, et al. Structure of the gene for human butyrylcholinestrase. Evidence for a single copy. Biochemistry 1990;29:124–31.
   PubMed Web of Science ®Google Scholar
• De Vriese C, Gregoire F, Lema-Kisoka R, et al. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 2004;145:4997–5005.
   PubMed Web of Science ®Google Scholar
• Silver A. The biology of cholinesterases. Frontiers Biol. 1974;36:1–596.
   Google Scholar
• Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989;260:625–34.
   PubMed Web of Science ®Google Scholar
• Hall LMC, Spierer P. The Ache locus of Drosophila melanogaster: structural gene for acetylcholinesterase with an unusual 5´leader. EMBO J 1986;5:2949–54.
   PubMed Web of Science ®Google Scholar
• Pritchard D, Brown A, Toutant J. The molecular forms of acetylcholinesterase from Neceuor americanus (nematoda), a hookworm parasite of the human intestine. Eur J Biochem 1994;219:317–23.
   PubMedGoogle Scholar
• Toutant J. Insect acetylcholinesterase: catalytic properties, tissue distribution and molecular forms. Prog Neurobiol 1989;32:423–46.
   PubMed Web of Science ®Google Scholar
• Johnson G, Moore SW. Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. Neurochem Int 2012;61:783–97.
   PubMed Web of Science ®Google Scholar
• Darvesh S, Grantham D, Hopkins D. Neurobiology of butyrylcholinesterase. J Comp Neurol 1998;393:374–90.
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA, Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463:25–43.
   PubMed Web of Science ®Google Scholar
• Wescoe WC, Hunt CH, Riker WF, et al. Regeneration rates of serum cholinesterase in normal individuals and in patients with liver damage. Am J Physiol 1947;149:158–63.
   Google Scholar
• Manoharan I, Boopathy R, Darvesh S, et al. A medial health report on individuals with silent butyrylcholinesterase in Vysya community of India. Clin Chim Acta 2007;378:128–35.
   PubMed Web of Science ®Google Scholar
• Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharm Therap 2015;148:34–46.
   PubMed Web of Science ®Google Scholar
• Lampón N, Hermida-Cadahia EF, Riveiro A, et al. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 2012;11:356–63.
   PubMed Web of Science ®Google Scholar
• Whittaker M. Plasma cholinesterase variants and the anaesthetist. Annesthesia 1980;35:174–97.
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273–7.
   PubMed Web of Science ®Google Scholar
• Arendt T, Bruckner M, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer´s disease resemble embryonic development – a study of molecular forms. Neurochem Int 1992;21:381–96.
   PubMed Web of Science ®Google Scholar
• Simão-Silva DP, Bertolucci PHF, Labio RW, et al. Association analysis between K and 116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population. Chem Biol Interact 2013;203:358–60.
   PubMed Web of Science ®Google Scholar
• Rubinstein HM, Dietz AA, Lubrano T. E1K, another quantitative variant at cholinesterase locus 1. J Med Genet 1978;(15):27–9.
   PubMed Web of Science ®Google Scholar
• Furtado-Alle L, Andrade FA, Nunes K, et al. Chautard-Freire-Maia EA: Association of variants of the 116 site of the butyrylcholinesterase BCHE gene to enzyme activity and body mass index. Chem Biol Interact 2008;175:115–8.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Darreh-Shori T, Rongve A et al. Association of butyrylcholinesterase-K allele and apolipoprotein E4 allele with cognitive decline in dementia with Lewy bodies and Alzheimer´s disease. J Alzheimer Dis 2016;50(2):567–76.
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, et al. DbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308–11.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer´s disease: recommendations from the National Institute on Aging and Alzheimer´s Association workgroup. Alzheimer's Dement 2011;7:263–9.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863–72.
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Nurnberger JL. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
   PubMed Web of Science ®Google Scholar
• Dietz AA, Rubinstein HM, Lubrano T. Improved method for the differentiation of cholinesterase variants. Am J Genet 1972;24:58–64.
   Web of Science ®Google Scholar
• Clump Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97–105.
   PubMed Web of Science ®Google Scholar
• Atack JR, Perry EK, Bonhan JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterasein the aged human central nervous system. J Neurochem 1986;47:263–77.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson´s disease. N Engl J Med 2004;24:2509–18.
   Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456–61.
   PubMed Web of Science ®Google Scholar
• Lockridge O, Duysen EG, Masson P. Butyrylcholinesterase: overview structure and function. In: Satoh T, Gupta RC, eds. Anticholinesterase pesticides: metabolism, neurotoxicity and epidemiology. Hoboken, NJ: John Wiley & Sons, Inc.; 2011:25–41.
   Google Scholar
• Bartels CF, Van Der Spek AFL, La Du BN. Two polymorphisms in the non-coding regions of the BCHE gene. Nucleic Acids Res 1990;18:6171.
   PubMed Web of Science ®Google Scholar
• Singleton AB, Gibson AM, Edwardson JA, et al. Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet 1998;351:1818.
   PubMed Web of Science ®Google Scholar
• Lane R, He Y, Morris C, et al. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009;24:392–400.
   PubMed Web of Science ®Google Scholar
• Granham C, Ballard C, Saad K. Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer´s disease. Int Geriatr Psychiatry 1997;12:1113–24.
   Web of Science ®Google Scholar
• Shimada H, Hirano S, Sinotoh H, et al. Dementia with Lewy bodies can be well differentiated from Alzheimer´s disease by measurement of brain acetylcholinesterase activity – a 11CMP4A PET study. Int J Geriatr Psychiatry 2015;30:1105–13.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Carchexia Sarcopenia Muscle 2013;4:31–9.
   PubMed Web of Science ®Google Scholar